What is Enfuvirtide?
Enfuvirtide (brand name FUZEON, development codes T-20 / DP-178 / pentafuside) is a synthetic 36-amino-acid peptide that inhibits HIV-1 entry into target cells. It was approved by the FDA on March 13, 2003 as the first-in-class HIV fusion inhibitor, expanding the pre-existing antiretroviral arsenal (NRTIs, NNRTIs, protease inhibitors) to include a completely novel mechanism that operates outside the cell.
Enfuvirtide is administered as a twice-daily subcutaneous injection — a substantial dosing burden that has limited its use to salvage regimens for treatment-experienced patients with multidrug-resistant HIV-1.
Structure and Origin
Enfuvirtide's amino acid sequence is derived from the heptad repeat 2 (HR2) region of the HIV-1 envelope glycoprotein gp41. Native HIV gp41 contains two heptad repeat regions (HR1 and HR2) that fold together during viral entry to drive membrane fusion. Enfuvirtide is essentially the HR2 sequence presented as a free peptide that competitively binds HR1 and prevents fold-back.
The peptide is produced by solid-phase peptide synthesis at large scale — at the time of approval, enfuvirtide was the largest synthetic peptide commercial pharmaceutical product ever produced (4,492 Da, 36 residues).
Mechanism of Action
HIV-1 entry is a multi-step process:
- gp120 (envelope subunit) binds CD4 on the host cell
- gp120 then binds CCR5 or CXCR4 co-receptor
- gp41 transmembrane subunit refolds: HR1 and HR2 fold together to form a six-helix bundle
- The six-helix bundle pulls viral and cellular membranes together for fusion
- Viral capsid enters the cytoplasm
Enfuvirtide inserts itself between HR1 and the natural HR2 sequence on viral gp41, physically blocking the six-helix bundle from forming. Without this fold, the membranes cannot fuse, and viral entry is aborted.
Clinical Evidence
TORO 1 and TORO 2 trials (NEJM 2003):
- 995 treatment-experienced HIV patients on optimized background regimen ± enfuvirtide
- Greater HIV-1 RNA reduction in enfuvirtide arm (-1.696 log10 vs -0.764 log10 at week 24)
- Greater rate of virologic suppression to <400 copies/mL
- Established enfuvirtide as effective salvage therapy for drug-resistant HIV
Approval History
- March 13, 2003 — FDA approval for treatment of HIV-1 infection in combination with other antiretroviral agents
- May 2003 — EMA approval
- Has remained on market continuously since 2003 despite limited use
Place in Therapy
Enfuvirtide's role has narrowed significantly since 2003 because:
- Newer drug classes — integrase inhibitors (raltegravir 2007, dolutegravir 2013, bictegravir 2018), CCR5 antagonists (maraviroc 2007), oral entry inhibitors, and capsid inhibitors (lenacapavir 2022) provide more convenient salvage options
- Twice-daily SC injection burden — most patients prefer once-daily oral or long-acting injectable regimens
- Injection-site reactions — approximately 98% of patients develop injection-site reactions
Enfuvirtide is now reserved for patients with extensive multi-class drug resistance who have exhausted other options. Even in this niche, lenacapavir (long-acting capsid inhibitor) has reduced demand for enfuvirtide.
Safety Profile
The dominant adverse events are:
- Injection-site reactions (~98% of patients) — pain, induration, erythema, nodules; cumulative over treatment duration
- Pneumonia — increased rate
- Hypersensitivity reactions — rare but severe, including angioedema and respiratory distress
The peptide is well-tolerated systemically; the local SC injection burden is the dominant tolerability problem.
Why It Matters
Enfuvirtide's 2003 approval was a landmark in peptide antiviral therapy:
- Validated the gp41 fusion mechanism as a druggable target
- Demonstrated that synthetic peptides at industrial scale could be commercially viable antivirals
- Inspired follow-on peptide entry inhibitors and a broader interest in viral entry as a drug target
- Spawned subsequent gp41-targeted peptides (sifuvirtide, albuvirtide approved in China)
It remains the canonical example of structure-based peptide drug design from a viral protein.